文章核心观点 华尔街分析师预计百健公司即将公布的季度报告中每股收益为3.45美元，同比增长17%，营收预计达24.2亿美元，同比增长1.3%，过去30天该季度每股收益共识预期向下修正0.7%，分析关键指标预测能更全面了解公司业务表现 [1][2][4] 盈利预测相关 - 分析师预计公司即将公布的季度每股收益为3.45美元，同比增长17% [1] - 预计营收达24.2亿美元，同比增长1.3% [1] - 过去30天该季度每股收益共识预期向下修正0.7% [2] 关键指标预测 - “Revenue - Product - Multiple Sclerosis (MS) - TYSABRI - Total”预计达3.9422亿美元，同比变化-15.2% [5] - “Revenue - Product - Rare Disease - SPINRAZA - Total”预计为4.161亿美元，同比变化+0.9% [5] - “Revenue - Anti - CD20 therapeutic programs”预计达4.4252亿美元，同比变化+1.5% [6] - “Revenue - Product, net”预计达18.1亿美元，同比变化-1% [6] - “Revenue - Product - Multiple Sclerosis (MS) - TYSABRI - United States”预计为2.1454亿美元，同比变化-13.4% [7] - “Revenue - Product - Multiple Sclerosis (MS) - Fumarate - TECFIDERA - Rest of world”预计达1.818亿美元，同比变化+0.7% [7] - “Revenue - Product - Multiple Sclerosis (MS) - TYSABRI - Rest of world”预计达1.7774亿美元，同比变化-18.1% [8] - “Revenue - Product - Multiple Sclerosis (MS) - Fumarate - TECFIDERA - United States”预计为3962万美元，同比变化-37.9% [8] - “Revenue - Product - Rare Disease - SPINRAZA - United States”预计为1.5654亿美元，同比变化-0.6% [9] - “Revenue - Product - Multiple Sclerosis (MS) - Interferon - Rest of world”预计为9793万美元，同比变化-10.7% [9] - “Revenue - Product - Multiple Sclerosis (MS) - Interferon - United States”预计达1.4099亿美元，同比变化-17.2% [10] - “Revenue - Product - Rare Disease - SPINRAZA - Rest of World”预计达2.5608亿美元，同比变化+0.4% [10] 股价表现 - 百健公司股价过去一个月变化-5.6%，同期Zacks标准普尔500综合指数变化+1.9% [10] - 公司Zacks排名为3（持有），预计近期表现与整体市场一致 [10]